Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's pipeline also includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease and epilepsy, all of which are available for partnering. Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN"). For more information please visit www.amarincorp.com. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.99 |
| Quarterly EPS Est: | -0.38 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.29 |
Data is provided by Zacks Investment Research

